Proteins are kind of natural molecules that show unique functionalities and properties in biological materials and manufacturing field. There are numerous nanomaterials which are derived from protein, albumin, and gelatine. These nanoparticles have promising properties like biodegradability, no antigenicity, metabolizable, surface modifier, greater stability during in vivo during storage, and being relatively easy to prepare and monitor the size of the particles. These particles have the ability to attach covalently with drug and ligands. Protein nanoparticles can be used in various targeted therapies, namely, pulmonary delivery, cancer therapy, tumour therapy, and vaccines, in which protein nanoparticles can be incorporated into biodegradable polymer in the form of microspheres for controlled and sustained release. The major aim in designing nanoparticle as a drug delivery system is to control particle size, surface area, and surface properties so that the nanoparticles carrying required amount of drug show desired pharmacological activity by releasing actives in order to achieve site-specific action. Proteins nanoparticles have certain unique functionalities and potential applications in both biomedical and material sciences. They are recommended as ideal material for the preparation of nanoparticles because of their amphiphilicity which allow the nanoparticles to interact with both the drug and solvent. Nanoparticles derived from natural proteins are biodegradable, metabolizable, and easily adaptable to surface modifications to allow attachment of drug and targeting ligands. They can be synthesized from various protein including water soluble proteins.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico